Mersana Therapeutics mit neuer ADC-Technologie
eröffnet am 17.10.17 00:17:25 von
neuester Beitrag 27.07.23 16:17:39 von
neuester Beitrag 27.07.23 16:17:39 von
Beiträge: 46
ID: 1.264.315
ID: 1.264.315
Aufrufe heute: 2
Gesamt: 4.263
Gesamt: 4.263
Aktive User: 0
ISIN: US59045L1061 · WKN: A2DTR7 · Symbol: 0M4
2,3890
EUR
-3,75 %
-0,0930 EUR
Letzter Kurs 17:01:38 Tradegate
Neuigkeiten
09.05.24 · globenewswire  |
03.05.24 · globenewswire |
02.05.24 · globenewswire |
04.04.24 · globenewswire |
04.03.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 9,4850 | +125,91 | |
| 17,140 | +42,12 | |
| 1,3300 | +30,51 | |
| 2,0000 | +29,03 | |
| 1,9800 | +26,11 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7200 | -18,18 | |
| 5,7500 | -18,44 | |
| 1,7680 | -18,75 | |
| 2,8800 | -28,71 | |
| 3,5200 | -74,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 73.778.700 von faultcode am 03.05.23 17:33:24Zack zack 😉✌️
Zack!
mMn. Mersana wappnet sich gegen.....
https://quantisnow.com/insight/4281665
● Revise and enhance, in light of the universal proxy rules adopted by the Securities and Exchange Commission, procedural mechanics and disclosure requirements in connection with stockholder nominations of directors and submission of proposals regarding other business at stockholder meetings by:
Providing that if any stockholder, beneficial owner and/or Stockholder Associated Person that intends to solicit proxies in support of any nominees other than the Company’s nominees provides the notice and information required by Rule 14a-19(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), then such stockholder, beneficial owner and/or Stockholder Associated Person, upon request by the Company, must provide to the Company no later than five business days prior to the applicable meeting, reasonable evidence that it has met the requirements of soliciting the holders of shares of at least 67% of the voting power of shares entitled to vote on the election of directors and including a statement to that effect in the proxy statement or form of proxy
● Limit the number of nominees that a stockholder may nominate to the number of directors to be elected at such meeting;
● Add an emergency by-law provision to provide clarity and authority to directors and certain officers during an emergency situation that would otherwise prevent a quorum of the Board or a Board committee from being achieved.
https://quantisnow.com/insight/4281665
● Revise and enhance, in light of the universal proxy rules adopted by the Securities and Exchange Commission, procedural mechanics and disclosure requirements in connection with stockholder nominations of directors and submission of proposals regarding other business at stockholder meetings by:
Providing that if any stockholder, beneficial owner and/or Stockholder Associated Person that intends to solicit proxies in support of any nominees other than the Company’s nominees provides the notice and information required by Rule 14a-19(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), then such stockholder, beneficial owner and/or Stockholder Associated Person, upon request by the Company, must provide to the Company no later than five business days prior to the applicable meeting, reasonable evidence that it has met the requirements of soliciting the holders of shares of at least 67% of the voting power of shares entitled to vote on the election of directors and including a statement to that effect in the proxy statement or form of proxy
● Limit the number of nominees that a stockholder may nominate to the number of directors to be elected at such meeting;
● Add an emergency by-law provision to provide clarity and authority to directors and certain officers during an emergency situation that would otherwise prevent a quorum of the Board or a Board committee from being achieved.
Nach Janssen und GSK...
Mersana signs deal with Merck KGaA for cancer therapy development
Mersana Therapeutics Inc said on Thursday it had signed a deal for developing cancer drugs with Germany's Merck KGaA that has the potential to generate up to $800 million in milestone payments.
Mersana would receive $30 million in an upfront payment, which would be used to develop drugs known as antibody-drug conjugates (ADCs), the company said.
Under the agreement, Mersana would develop cancer drug candidates against up to two targets that would utilize its platform to combine Merck KGaA's proprietary antibodies.
Mersana said it was also eligible to receive royalties of up to low double-digit percentages on global net sales for any approved ADCs that are developed under the agreement.
https://finance.yahoo.com/news/mersana-signs-deal-merck-kgaa…
Mersana signs deal with Merck KGaA for cancer therapy development
Mersana Therapeutics Inc said on Thursday it had signed a deal for developing cancer drugs with Germany's Merck KGaA that has the potential to generate up to $800 million in milestone payments.
Mersana would receive $30 million in an upfront payment, which would be used to develop drugs known as antibody-drug conjugates (ADCs), the company said.
Under the agreement, Mersana would develop cancer drug candidates against up to two targets that would utilize its platform to combine Merck KGaA's proprietary antibodies.
Mersana said it was also eligible to receive royalties of up to low double-digit percentages on global net sales for any approved ADCs that are developed under the agreement.
https://finance.yahoo.com/news/mersana-signs-deal-merck-kgaa…
Trading Spotlight
Schöner Anstieg heute. Gibt's News?
Antwort auf Beitrag Nr.: 70.736.811 von pako21 am 03.02.22 18:54:10
Die nächste Vereinbarung ...dieses Mal mit GSK:
Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2
- GSK receives exclusive global license option for XMT-2056
- Mersana to receive $100 million upfront option purchase fee
- If GSK exercises its option, Mersana to receive exercise payment; potential for additional development, regulatory and commercial milestone payments, plus tiered double-digit royalties on net sales
- Mersana to co-develop XMT-2056; retains options for U.S. profit-sharing and U.S. co-promotion
https://finance.yahoo.com/news/mersana-therapeutics-announce…
Zitat von pako21: Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates
- Collaboration focused on discovering novel ADCs for three targets by leveraging Mersana’s ADC
expertise and the Dolasynthen platform with Janssen’s (one of the Janssen Pharmaceutical
Companies of Johnson & Johnson) proprietary antibodies
- Mersana receives $40 million upfront payment and potentially more than $1 billion in total
milestones, plus mid-single-digit to low double-digit percentage royalties on net sales
https://finance.yahoo.com/news/mersana-therapeutics-announce…
Ich habe nach dieser Meldung meine Position zum Kurs 3,86 EUR aufgestockt.
Die nächste Vereinbarung ...dieses Mal mit GSK:
Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2
- GSK receives exclusive global license option for XMT-2056
- Mersana to receive $100 million upfront option purchase fee
- If GSK exercises its option, Mersana to receive exercise payment; potential for additional development, regulatory and commercial milestone payments, plus tiered double-digit royalties on net sales
- Mersana to co-develop XMT-2056; retains options for U.S. profit-sharing and U.S. co-promotion
https://finance.yahoo.com/news/mersana-therapeutics-announce…
In den USA heute +10%
Zahlen sind mittelprächtig,die Aussichten weiterhin sehr gut meiner Meinung nach
Am 28. Februar geben sie eine Telefokonferenz zu den Q4 Zahlen plus anschließenden Buisness
Update,bin mal gespannt
Update,bin mal gespannt
Durchsuchen
04.03.24 · wallstreetONLINE Redaktion · Vertex Pharmaceuticals |
29.02.24 · wO Chartvergleich · Boston Beer (A) |